Literature DB >> 7684909

[Rapid diagnosis of paroxysmal nocturnal hemoglobinuria by gel test agglutination].

J M Navenot1, D Bernard, Y Petit-Frioux, M J Loirat, J Guimbretière, J Y Muller, D Blanchard.   

Abstract

Murine monoclonal antibodies (MoAbs) directed against DAF (Decay Accelerating Factor, CD55 antigen) and MIRL (Membrane Inhibitor of Reactive Lysis, CD59 antigen) were used to identify the affected red cells (CD55-/CD59-) of PNH patients. MoAbs NaM16-4D3 (CD55, IgG2a) and NaM77-1E5 (CD59, IgG3) weakly agglutinate red cells and represent powerful tools to quantitate normal (PNHI) and abnormal (PNHII and PNHIII) cells from PNH patients by indirect flow cytometry. MoAbs NaM125-7H10 (CD55) and NaM123-6G12 (CD59), both IgM, were selected for their agglutinating properties and used for the separation of PNHI from PNHII and PNHIII red cells by the gel test technology. From analysis of artificial mixtures of DAF+ and DAF- cells, a direct relationship was established between fluorescent cells detected by flow cytometry, and erythrocytes agglutinated in microtyping cards. The method was further confirmed by analysis of ten blood samples from PHN patients and represent an alternative to classical hemolysis tests. On the basis of our experience we propose the following for the diagnosis of PNH: 1) agglutination test with NaCl microtyping cards using IgM CD55 and CD59; 2) flow cytometry analysis for accurate quantitation of CD55-/CD59- red cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7684909     DOI: 10.1016/s1140-4639(05)80230-8

Source DB:  PubMed          Journal:  Rev Fr Transfus Hemobiol        ISSN: 1140-4639


  1 in total

1.  AOHE: manuscript AOHE-D-16-00564 paroxysmal nocturnal hemoglobinuria with autoimmune hemolytic anemia following eculizumab therapy-with large granular lymphocytic leukemia.

Authors:  Nathan Visweshwar; Michael Jaglal; Cassie Booth; Patrick Griffin; Damian Laber
Journal:  Ann Hematol       Date:  2016-07-23       Impact factor: 3.673

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.